Prior to Prometheus, Mr. Stenhouse spent over 25 years at AbbVie, most recently serving as Vice President ... Special consideration should be given to the potential hurdles of clinical and ...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax ...

The team includes Bob Whitehead (Executive Chairman), a veteran in the bioscience field known for successful strategic exits and initiatives; Ramakrishna Venugopalan, PhD (Co-Founder & CEO), a former ...

On 14 November, Eli Lilly became a part of this group, after an account using its name and logo ... pharma companies, HCPs, and patients that rely on the platform for communication. Pharma giant ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Brian Skorney has given his Buy rating due to a combination of factors including the recent failure of AbbVie’s emraclidine in Phase ... Inc. operates as a product based bio-pharmaceutical company. It ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...